Skip to main content
. 2022 May 23;6(15):4506–4515. doi: 10.1182/bloodadvances.2021006713

Figure 1.

Figure 1

Depth of response. Best overall response (A) and MRD negativity rate (B). *Adaptive Biotechnologies NGS, MRD testing performed at time of VGPR or CR. Per protocol, the CR was not tested at the time of the interim analysis because the Hydrashift M-protein interference assay38 was not yet available at that time. †Stratified Cochran-Mantel-Haenszel test. One-sided significance level is .025. ‡Provided for descriptive purposes only. ITT, intention-to-treat; ORR, overall response rate.